Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.

Cancer research - 15 Jan 2025

Bae Tae Hyun, Sung Ki Woon, Pham Tri M, Najy Abdo J, Zamiri Alaleh, Jang Hyejeong, Mun Su Ran, Kim Seongho, Kwon Ha Kyoung, Son Yeon Sung, Shi Dongping, Kregel Steven, Heath Elisabeth I, Cher Michael L, Kwon Yong Tae, Kim Hyeong-Reh Choi

Abstract excerpt

Genetic alterations play a pivotal role in various human diseases, particularly cancer. The androgen receptor (AR) is a crucial transcription factor driving prostate cancer progression across all stages. Current AR-targeting therapies utilize competitive AR antagonists or pathway suppressors. However, therapy resistance often emerges due to AR mutations and AR splice variants, such as AR-v7. To overcome this, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Proteolysis

Share to Receptors, Androgen

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39531508
DOI: 10.1158/0008-5472.CAN-24-0591
PMCID: PMC11733533

Genes

AR
SQSTM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.PMID 39531508Read ↗

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerSemantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degraderSemantic proximity Read ↗

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.Semantic proximity Read ↗

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor DegraderSemantic proximity Read ↗

PROTACs in the Management of Prostate Cancer.Semantic proximity Read ↗

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read ↗

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerSemantic proximity Read ↗

Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMASemantic proximity Read ↗

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancerSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.